Table 6 Incidence of adverse events after treatment in the two groups
| Â | Group | Chi-square test (P value) | |||
|---|---|---|---|---|---|
PSE + Hep + DEX group (N = 54) | PSE group (N = 62) | ||||
Abdominal pain | No | Count (%) | 29 (53.7%) | 21 (33.9%) | 0.039 |
| Â | Yes | Count (%) | 25 (46.3%) | 41 (66.1%) | Â |
Fever | No | Count (%) | 33 (61.1%) | 15 (24.2%) | 0.000 |
| Â | Yes | Count (%) | 21 (38.9%) | 47 (75.8%) | Â |
Vomiting | No | Count (%) | 46 (85.2%) | 47 (75.8%) | 0.248 |
| Â | Yes | Count (%) | 8 (14.8%) | 15 (24.2%) | Â |
Hydrothorax | No | Count (%) | 45 (83.3%) | 43 (69.4%) | 0.079 |
| Â | Yes | Count (%) | 9 (16.7%) | 19 (30.6%) | Â |
Ascites | No | Count (%) | 41 (75.9%) | 38 (61.3%) | 0.092 |
| Â | Yes | Count (%) | 13 (24.1%) | 24 (38.7%) | Â |
Portal vein thrombosis | No | Count (%) | 53 (98.1%) | 54 (87.1%) | 0.026 |
| Â | Yes | Count (%) | 1 (1.9%) | 8 (12.9%) | Â |
Splenic abscess | No | Count (%) | 54 (100.0%) | 61 (98.4%) | 0.349 |
| Â | Yes | Count (%) | 0 (0.0%) | 1 (1.6%) | Â |
Refractory ascites | No | Count (%) | 51 (94.4%) | 50 (80.6%) | 0.027 |
| Â | Yes | Count (%) | 3 (5.6%) | 12 (19.4%) | Â |